All lobbying filings

TODD STRATEGY GROUP

Lobbying for GILEAD SCIENCES, INC. · American biotechnology company that researches, develops and commercializes drugs.

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2026 · California · House · Senate · $80,000.00 income · posted Jul 20, 2026

Official filing document

Lobbying activity 1

Health Issues

Prescription drug payment reform. Supply Chain. 340B Program. Implementation of Inflation Reduction Act of 2022. General HIV policy. Prescrption drug pricing policy.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.